Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144936 · ClinicalTrials.gov registry record · Phase 1
Study of VX-985 in Subjects With Chronic Hepatitis C
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01144936 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 21 participants.
The verdict
NCT01144936, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.
Interventions
- DRUG VX-985 or matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144936
The ClinicalTrials.gov registry entry for NCT01144936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-985 or matching placebo is the first listed.
NCT01144936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144936 about?
NCT01144936 is a clinical study titled "Study of VX-985 in Subjects With Chronic Hepatitis C". The purpose of this study it to evaluate the safety and tolerability of VX-985 in HCV subjects. This study will also evaluate the antiviral activity and pharmacokinetic profile of VX-985.
What is the current status of trial NCT01144936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01144936?
The interventions under investigation include: VX-985 or matching placebo (DRUG).
Who is sponsoring clinical trial NCT01144936?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.